Old doc, new data: Canaglifozin Can-I-get-a-flozin? Dr Casey Parker examines new evidence for the diabetes medication.
Metabolic disorder drug listed on the PBS The listing will save patients with hyperphenylalaninemia more than $90,000 a year.
Potentially ‘life changing’ arthritis drug listed on PBS Tofacitinib will be listed despite lingering concerns related to an increased risk of blood clots and potentially death when taken in high doses.
Backdown on dispensing puts profits ahead of patients: RACGP The RACGP has criticised the Pharmacy Guild for reportedly forcing the Government to back away from plans for 60-day dispenses.
Cheaper treatments for cancer, Parkinson’s and motor neurone patients Changes to the Pharmaceutical Benefits Scheme will see some patients saving up to $300,000 per year.
Commercial sensitivity or patient protection? Secrecy and medicine safety Researchers have identified an information gap between pharmacological companies and Australian clinicians on the potential safety risks of medicines.
Important psoriatic arthritis drug listed on the PBS Ixekizumab is available for patients with the life-long condition, which causes joints to become stiff, painful and often swollen.
Four ‘breakthrough’ cancer drugs added to the PBS Almost 2000 people with leukaemia, advanced kidney cancer, bladder cancer and liver cancer will have affordable access to new treatment options.
Undisclosed pharmaceutical payments ‘a cause for concern’ A drop in disclosures related to pharmaceutical company payments to the Australian healthcare sector has prompted calls for more transparency.
PBS listing could save psoriasis patients tens of thousands a year Two effective – yet underutilised – psoriasis treatments have been added to the PBS, potentially reducing the cost by $32k per year.